Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
Semaglutide and pancreatic cancer risk
A 2026 meta-analysis of randomised trials found no increased pancreatic cancer risk with semaglutide, consistent with two earlier reviews of the GLP-1 class.
Semaglutide QoL gains: real but modest
A 2026 meta-analysis finds semaglutide 2.4 mg improves physical functioning scores, but gains fall below clinically meaningful thresholds.
Semaglutide vs dulaglutide in UK practice
A UK cohort study of 6,616 adults found semaglutide lowered HbA1c by 0.22 points more than dulaglutide over one year, with 1.92 kg more weight loss.
Boerhaave syndrome after semaglutide use
A 2026 case report describes the first documented esophageal perforation linked to GLP-1 agonist-induced vomiting after skipping dose titration.
Oral semaglutide for weight loss, reviewed
A Postgraduate Medicine review examines the trial evidence, dosing requirements, and practical considerations for using oral semaglutide in weight management.
Peptides for nerve recovery after surgery
BPC-157, TB-500, and ARA 290 are discussed in recovery communities after nerve surgery. Here is what preclinical and early clinical evidence actually shows.
Why your Semax or Selank spray smells off
A fishy or sulfurous smell from a pre-mixed peptide nasal spray usually signals degradation. The methionine chemistry explains why.
Switching Peptides: What the Evidence Says
No clinical guideline covers switching between incretin-class peptides. Prescribing information and early research both say: start at the lowest dose.
BPC-157 tested as AChE inhibitor in vitro
A 2026 lab study finds BPC-157 and two hybrid peptides inhibit the enzyme targeted by Alzheimer's drugs, but at low potency and only in vitro.
Which drugs flag for gastric motility risks
A 2026 study screened 58 million adverse-event reports. Semaglutide had the strongest signal for impaired gastric emptying.
Herbs for GLP-1 side effects? A new study
Researchers screened 142,705 FDA adverse event reports to flag five herbal candidates linked to GLP-1 side-effect pathways.
Oral Wegovy tracker: FDA, EMA, MHRA
The FDA, EMA, and MHRA have now all approved oral Wegovy for weight management. Here is the regulatory timeline and how the three decisions compare.